With evidenced roles in promoting primary tumour growth in a number of tumour types, while also driving metastatic spread (the primary cause of cancer patient deaths), suppressing BCL3 would seem to have dual benefits in providing clinically measurable beneficial outcomes on primary tumour growth while also potentially providing significant benefits for long term survival. Here, BCL3 is linked to cancer.